<?xml version="1.0" encoding="UTF-8"?>
<ONIXMessage release="3.0" xmlns="http://ns.editeur.org/onix/3.0/reference" >
<Header><Sender><SenderName>unglue.it</SenderName><EmailAddress>unglueit@ebookfoundation.org</EmailAddress></Sender><SentDateTime>20260712T211402Z</SentDateTime><MessageNote>Unglue.it Malaria</MessageNote></Header><Product><RecordReference>it.unglue.work.519269.695416</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>695416</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Advances in Microfluidics Technology for Diagnostics and Detection</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>David Kinahan</PersonName><PersonNameInverted>Kinahan, David</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Dario Mager</PersonName><PersonNameInverted>Mager, Dario</PersonNameInverted></Contributor><Contributor><SequenceNumber>3</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Elizaveta Vereshchagina</PersonName><PersonNameInverted>Vereshchagina, Elizaveta</PersonNameInverted></Contributor><Contributor><SequenceNumber>4</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Celina Miyazaki</PersonName><PersonNameInverted>Miyazaki, Celina</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>arboviruses</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biosensors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>centrifugal microfluidics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>centrifugal step emulsification</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>compact</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COVID-19</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Detection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>digital droplet polymerase chain reaction (ddPCR)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>droplet fluorescence evaluation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>droplet stability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insecticide resistances</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>LabDisk</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lipoplex</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>LoaD platforms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Microfluidics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mosquito monitoring</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Multiplexing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nano-qPCR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nanoparticle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pirani</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PoC devices</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>polyplex</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Python</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Raspberry Pi</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SARS-CoV-2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SAW</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sensing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>siRNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ultra-sensitive</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Vacuum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Vector-borne diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>viral load</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>viral RNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>wireless</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Microfluidics and lab-on-a-chip have, in recent years, come to the forefront in diagnostics and detection. At point-of-care, in the emergency room, and at the hospital bed or GP clinic, lab-on-a-chip offers the potential to rapidly detect time-critical and life-threatening diseases such as sepsis and bacterial meningitis. Furthermore, portable and user-friendly diagnostic platforms can enable disease diagnostics and detection in resource-poor settings where centralised laboratory facilities may not be available. At point-of-use, microfluidics and lab-on-chip can be applied in the field to rapidly identify plant pathogens, thus reducing the need for damaging broad spectrum pesticides while also reducing food losses. Microfluidics can also be applied to the continuous monitoring of water quality and can support policy-makers and protection agencies in protecting the environment. Perhaps most excitingly, microfluidics also offers the potential to enable entirely new diagnostic tests that cannot be implemented using conventional laboratory tools. Examples of microfluidics at the frontier of new medical diagnostic tests include early detection of cancers through circulating tumour cells (CTCs) and highly sensitive genetic tests using droplet-based digital PCR.This Special Issue on “Advances in Microfluidics Technology for Diagnostics and Detection” aims to gather outstanding research and to carry out comprehensive coverage of all aspects related to microfluidics in diagnostics and detection.<br/><br/>Listed by <a href="https://unglue.it/work/519269/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/08/b3/08b37f1a232e75dd3c813a97816ee497.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2021</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/368519/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.502460.672916</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>672916</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E101</ProductFormDetail><ProductFormDetail>E116</ProductFormDetail><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>PD-US</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/about/pdm</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>An Enquiry Into the Origin and Intimate Nature of Malaria</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Thomas Wilson, active</PersonName><PersonNameInverted>active, Thomas Wilson,</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GITenberg</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>03</SubjectSchemeIdentifier><SubjectCode>RC</SubjectCode></Subject></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div><br/><br/>Listed by <a href="https://unglue.it/work/502460/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/86/82/86820ff12f5d8a61598366668d2a5c2a.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>Project Gutenberg</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>20190922</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">epub file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/339092/</WebsiteLink></Website><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">mobi file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/339093/</WebsiteLink></Website><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/339094/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.491969.659758</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>659758</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Antifungal and Antiparasitic Drug Delivery</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Juan José Torrado Durán</PersonName><PersonNameInverted>Durán, Juan José Torrado</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Dolores R. Serrano</PersonName><PersonNameInverted>Serrano, Dolores R.</PersonNameInverted></Contributor><Contributor><SequenceNumber>3</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Javier Capilla</PersonName><PersonNameInverted>Capilla, Javier</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adjuvants</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>AHCC®</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>amphotericin B</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>aspergillosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>azoles</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bioavailability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>butenafine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>calcium carbonate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>candidiasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chitosan</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>combined therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>controlled release</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cutaneous leishmaniasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cytotoxicity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Design of experiments</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Drug delivery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>emulsions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>enolase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fast-dissolving films</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fluconazole</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fungal infections</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hydrogel</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Leishmania infantum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>leishmaniasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lentinula edodes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>liposomes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>meglumine antimoniate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>micelles</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Molecular Envelope Technology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Montanide PetGel A</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nanoparticles</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral delivery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>orodispersible films</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>orthopedic infection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>poloxamer 407</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Poly(d,l-lactide-co-glycolide) beads</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>polymer micelles</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>praziquantel</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>quality by design</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reference, information &amp; interdisciplinary subjects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Research &amp; information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Schistosomiasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sepigel 305®</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>shiitake</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>skin and vaginal mucosa</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SNEDDS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>solid SNEDDS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>solubility</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sporothrix schenckii</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spray drying</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sustained release</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thermoreversible gel</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>toluene</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>topical treatment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transferosomes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>trypanosomiasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Vaccine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Virulence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>wound dressing</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>undefined<br/><br/>Listed by <a href="https://unglue.it/work/491969/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2020</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/465403/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.194960.290841</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>290841</IDValue></ProductIdentifier><ProductIdentifier><ProductIDType>03</ProductIDType><IDValue>9783863952570</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-SA</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-sa/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Armut und Gesundheit - Öffentliche Ringvorlesung Wintersemester 2013/2014</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Martin Tamcke</PersonName><PersonNameInverted>Tamcke, Martin</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Arundhati Roy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GIHN</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Göttingen International Health Network</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HIV</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HIV/AIDS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Maternal death</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Poverty</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>World Health Organization</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Der Zusammenhang von Armut und Krankheit, bzw. mangelnder Gesundheit, ist immer schon klar ersichtlich gewesen. In einer Vorlesungsreihe stellten Vertreter verschiedener Disziplinen, die sich im Göttingen International Health Network (GIHN) zusammengeschlossen haben, ausgewählte Aspekte vor, die darstellen, wie Armut und Gesundheit miteinander verknüpft sind. Die Fragen, Probleme, Erklärungs- und Interventionsmodelle beziehen sich besonders auf Afrika und Indien und Anrainerstaaten. Mit der Vorlesungsreihe stellten sich die Vertreter der verschiedenen Fächer bewusst einer allgemeineren Öffentlichkeit und bemühten sich, auch komplexe Themen verständlich und doch auf neuestem Stand der Forschung darzustellen.<p>Der Zusammenhang von Armut und Krankheit, bzw. mangelnder Gesundheit, ist immer schon klar ersichtlich gewesen. In einer Vorlesungsreihe stellten Vertreter verschiedener Disziplinen, die sich im Göttingen International Health Network (GIHN) zusammengeschlossen haben, ausgewählte Aspekte vor, die darstellen, wie Armut und Gesundheit miteinander verknüpft sind. Die Fragen, Probleme, Erklärungs- und Interventionsmodelle beziehen sich besonders auf Afrika und Indien und Anrainerstaaten. Mit der Vorlesungsreihe stellten sich die Vertreter der verschiedenen Fächer bewusst einer allgemeineren Öffentlichkeit und bemühten sich, auch komplexe Themen verständlich und doch auf neuestem Stand der Forschung darzustellen.<br/><br/>Listed by <a href="https://unglue.it/work/194960/">Unglue.it</a>.</p></div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/9c/28/9c287f7b7ed96dfce1723278a30defd3.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>Universitätsverlag Göttingen</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2016</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/319273/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.510195.683900</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>683900</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E116</ProductFormDetail><ProductFormDetail>E101</ProductFormDetail><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Artemisinin - From Traditional Chinese Medicine to Artemisinin Combination Therapies; Four Decades of Research on the Biochemistry, Physiology, and Breeding of Artemisia annua</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Tomasz Czechowski</PersonName><PersonNameInverted>Czechowski, Tomasz</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Ian A. Graham</PersonName><PersonNameInverted>Graham, Ian A.</PersonNameInverted></Contributor><Contributor><SequenceNumber>3</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Pamela J. Weathers</PersonName><PersonNameInverted>Weathers, Pamela J.</PersonNameInverted></Contributor><Contributor><SequenceNumber>4</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Peter E. Brodelius</PersonName><PersonNameInverted>Brodelius, Peter E.</PersonNameInverted></Contributor><Contributor><SequenceNumber>5</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Geoffrey Duncan Brown</PersonName><PersonNameInverted>Brown, Geoffrey Duncan</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Artemisia annua</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>artemisinin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biology, Life Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Botany &amp; plant sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>molecular breeding</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Science: general issues</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>semi-synthetics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::P Mathematics and Science::PD Science: general issues</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PST Botany and plant sciences</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact<br/><br/>Listed by <a href="https://unglue.it/work/510195/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/8f/85/8f85b21da5f7b7f6215c7fec84c77b83.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>Frontiers Media SA</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2020</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">mobi file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/355778/</WebsiteLink></Website><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">epub file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/352587/</WebsiteLink></Website><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/352586/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.457647.619342</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>619342</IDValue></ProductIdentifier><ProductIdentifier><ProductIDType>03</ProductIDType><IDValue>9783039285402</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Arthropod Venom Components and Their Potential Usage</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Katsuhiro Konno</PersonName><PersonNameInverted>Konno, Katsuhiro</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Gandhi Rádis-Baptista</PersonName><PersonNameInverted>Rádis-Baptista, Gandhi</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>acid-gated currents</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>acid-sensing ion channels</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Acinetobacter baumannii</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Alternative treatment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>AMP</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>amphipathic ?-helix structure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ANT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antifeedant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antimicrobial peptide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antivenoms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Ants</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Apoptosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>arthropod</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>automated patch-clamp</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bee venom</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Bees</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Berberomeloe majalis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bioinformatics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biotools</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>blister beetle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>brown spider</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cantharidin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Centruroides limpidus Karch</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Chagas Disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>channel-like pore-forming activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chemotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Chronic Pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cold allodynia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>computational docking</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cutaneous disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>de novo sequencing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dinoponera quadriceps</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>directed disulfide bond formation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>drug targets</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>envenomation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>FMRF-amide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Formicidae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>heart contractility</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>homology modelling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>human African trypanosomiasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hybrid immunogen</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hymenoptera</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hymenoptera venom</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ICK peptide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ICK-like toxins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>industrial biotechnology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insect immune system</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insect neurotoxin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insecticidal peptide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ion channel structure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ixodicide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>keratitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>knottins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>leishmaniasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>linear cationic ?-helical peptide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Loxosceles</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Loxosceles spp.</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>LTQ Orbitrap Hybrid Mass Spectrometer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>LyeTxI-b</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mass spectrometric analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mass spectrometry analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mastoparan</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mechanical allodynia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mechanism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>melittin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metalloproteases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>myrmecology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>natural antibiotics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NaV</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nav channel activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nav1.7</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nematicide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuropathic pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neutralizing antibodies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>novel therapeutics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oxaliplatin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pain target</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Peptides</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pH regulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Pharmacology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phospholipases D</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pilosulin-like peptide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>piperidine heterocyclic amines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>protein–peptide interactions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>proteome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Proteomics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>protons</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>recombinant toxins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>scorpion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>scorpion venom</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Skin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>small hive beetle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>solitary wasp</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spider toxin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spider venom</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Staphylococcus aureus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>stent</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Tenebrio molitor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tertiapin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>toxins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>toxoplasmosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transcriptome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>venom</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>venom allergens</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>venom peptides</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>venom toxicity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>virtual screening</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>voltage-gated sodium channel</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Wasps</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Thousands of arthropod species, ranging from arachnids (spiders and scorpions) to hymenopterans (ants, bees, and wasps) and myriapods (centipedes), are venomous and use their venoms for both defense and predation. These venoms are invariably harmful to humans, and some may cause serious injuries, e.g., those from scorpions, spiders, and wasps. Arthropods’ venoms are also known as rich sources of biologically active compounds and have attracted the attention of toxin researchers for years. In this century, venom component analysis has progressed considerable due to the advances in analytical techniques, in particular, mass spectrometry and next-generation deep (DNA and RNA) sequencing. As such, proteomic and peptidomic analyses using LC–MS have enabled the full analysis of venom components, revealing a variety of novel peptide and protein toxins sequences and scaffolds, potentially useful as pharmacological research tools and for the development of highly selective peptide ligands and therapeutic leads, like chlorotoxin. Due to their specificity for numerous ion-channel subtypes, including voltage- and ligand-gated ion channels, arthropod neurotoxins have been investigated to dissect and treat neurodegenerative diseases and control epileptic syndromes. This Special Issue collects information on such progress, encouraging contributions on the chemical and biological characterization of venom components, not only peptides and proteins, but also small molecules, their mechanisms of action, and the development of venom-derived peptide leads.<br/><br/>Listed by <a href="https://unglue.it/work/457647/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/cb/b7/cbb7b4269c012f9c4f3c2d5462f567c2.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>20200325</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/427521/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.411576.559451</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>559451</IDValue></ProductIdentifier><ProductIdentifier><ProductIDType>03</ProductIDType><IDValue>9783039211876</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Biological Potential and Medical Use of Secondary Metabolites</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Ana M. L Seca</PersonName><PersonNameInverted>Seca, Ana M. L</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Diana Cláudia Pinto</PersonName><PersonNameInverted>Pinto, Diana Cláudia</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>(-)-rabdosiin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ABTS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>amentoflavone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>analytical determination</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ancient varieties</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anti-inflammatory</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antibacterial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anticancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antimicrobial activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antimicrobial and anticancer activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antioxidant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antioxidant activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Antioxidants</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antiplasmodial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antiSMASH</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antitumor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Artemisia species</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Artemisia vachanica</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>artemisinin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ascorbic acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biological activities</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biosynthetic gene clusters</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Boswellia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>boswellic acids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bowel diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cannabinoids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cannabis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Celastraceae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cembranoids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cneorubenoids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cordycepin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cordyceps militaris</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cytotoxic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cytotoxic activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>defensins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>deoxypodophyllotoxin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diterpenes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DPPH</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>EGCG</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>essential oils</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Flavonoids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>frankincense</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>FRAP</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GC-MS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HPLC-PAD</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HPLC-PDA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>infectious diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>innate immunity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iridoids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Juniperus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kratom</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lamiaceae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>LC-MS/MS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>legalization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lignans</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Malus x domestica</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Maytenus chiapensis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>medicinal applications</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mitragyna speciosa</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>molecular docking</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nanoemulsion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Natural Products</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nutraceutics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Ocimum sanctum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pectin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pentacyclic triterpenoids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phenolic derivatives</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phytochemistry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plant defense</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Plants</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Polyphenols</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PPAR-?</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pristimerin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>quinonemethide triterpenoids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sargachromenoic acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sargahydroquinoic acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sarganaphthoquinoic acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sargaquinoic acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Scabiosa</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>seaweeds</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>secondary metabolites</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sugars</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Tajikistan</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TCM</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>therapeutic uses</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Therapeutics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tingenone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>total phenolics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Toxicology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>triterpenoids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Tuscany</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Vector control</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>xanthine oxidase</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Many macro and micro species, from terrestrial and aquatic environments, produce structurally unique compounds and, in many countries, still are the primary sources of medicines. In fact, secondary metabolites are an important source of chemotherapeutic agents but are also lead compounds for synthetic modification and the optimization of biological activity. Therefore, the exploitation of secondary metabolites, or their inspired synthetic compounds, offers excellent opportunities for the pharmaceutical industry. This Medicines Special Issue focuses on the great potential of secondary metabolites for therapeutic application. The Special Issue contains 16 articles reporting relevant experimental results, and an overview of bioactive secondary metabolites, their biological effects, and new methodologies that improve and accelerate the process of obtained lead compounds with regard to new drug development. We would like to thank all 83 authors, from all over the world, for their valuable contributions to this Special Issue.<br/><br/>Listed by <a href="https://unglue.it/work/411576/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/c8/b7/c8b7f54996932dac84f1856c722176df.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2019</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/305065/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.518551.694698</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>694698</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Carbon Ligands</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Yves Canac</PersonName><PersonNameInverted>Canac, Yves</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>195Pt NMR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>alkali metals</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>amide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>amino-acids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>aromaticity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>asymmetric synthesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>calixarene</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>carbenes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>carbido complexes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>carbodiphosphorane</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>carbon ligand</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>carbone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>carbone complexes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Catalysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chemical bonding</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Chirality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Coordination</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Coordination Chemistry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>copolymerization of epoxide with CO2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cu(I) complex</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cyclooctatetraene ions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dehydrogenation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>density functional theory</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>density functional theory (DFT)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DFT calculations</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>drug resistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>electrochemistry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>electron paramagnetic resonance (EPR) spectroscopy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>electronic structure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>germylene</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gold</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hafnium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hybrid molecules</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Imidazole</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intramolecular C-H activation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ion pairs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ligand</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Ligands</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lithium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>macrocycle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mercury(II) complex</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metal complexes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metathesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>N-heterocyclic carbene</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>N-heterocyclic carbenes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nanoparticle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>natural bond orbitals</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>negative charge</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NHC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NHC ligands</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NHC-ligands</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nitro catalysts</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>olefins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>optical resolution</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oxide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>palladium catalyst</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phosphonium ylide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phosphorus ylides</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Photoluminescence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pincer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pincer ligand</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pincer ligands</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plasmodium falciparum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Platinum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Potassium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>reactivity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reference, information &amp; interdisciplinary subjects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Research &amp; information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rhodium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ruthenium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>selenonium salts</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>selenonium ylides</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spectroscopy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>stereogenic selenium atom</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>structure–activity relationship</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Suzuki-Miyaura reaction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>T-shaped</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Titanium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transition metal complexes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tropylidenyl ions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Water</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>X-ray</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ylide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ylides</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Homogeneous catalysis owes its success, in large part, to the development of a wide range of ligands with well-defined electronic and steric properties, which have thus made it possible to adjust the behavior of many organometallic complexes. However, ligands used in catalysis have long been centered on elements of group 15, and it is only more recently that carbon ligands have proved to be valuable alternatives with the emergence of cyclic diaminocarbenes (NHC).This Special Issue aims to provide a contemporary overview of the advances in carbon ligand chemistry from fundamental aspects to applications.<br/><br/>Listed by <a href="https://unglue.it/work/518551/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/93/2e/932ec7121cfae777c8de0c41da2b76dd.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2021</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/368169/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.458726.620572</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>620572</IDValue></ProductIdentifier><ProductIdentifier><ProductIDType>03</ProductIDType><IDValue>9783039286980</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Circulating Tumor Cells</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Catherine Alix-Panabieres</PersonName><PersonNameInverted>Alix-Panabieres, Catherine</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>abiraterone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ACCEPT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>androgen receptor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>AR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>AR-V7</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ARV7</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarkers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bone Marrow</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Breast cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>castration resistant prostate cancer (CRPC)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CD133</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CellSearch</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CellSearch®</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cerebrospinal liquid biopsy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chemoradioresistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chromogranin A</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>circulating leukemia cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>circulating plasma cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>circulating tumor cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>circulating tumor cells (CTC)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>circulating tumor cells (CTCs)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>circulating tumor DNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>circulating tumour cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clinical trials</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clinical utility</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>colorectal cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Colorectal Surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CTC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CTC biology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CTC capture technology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CTC-based treatment decisions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CTC-derived ex vivo models</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CTC-derived xenografts</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CTCs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ctDNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CTM</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CTMat</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ctRNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>disseminated tumor cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>early breast cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>EasyCount slides</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>emboli</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>enrichment and detection technologies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>enzalutamide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>EpCAM enrichment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>EPISPOT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Epithelial-to-mesenchymal transition (EMT)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>epithelial–mesenchymal transition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>exosome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Exosomes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fibronectin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fish</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Flow Cytometry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>FOLFIRINOX</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gene expression analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Glioma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hematological cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hepatocellular carcinoma (HCC)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>heterogeneity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HMB-45</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immune checkpoint inhibitors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Immune system</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immunofluorescence imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Immunomodulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immunophenotyping</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>in vivo flow cytometry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>integrin B1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>leukocyte-derived extracellular vesicles</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Liquid Biopsy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>liquid surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>locally advanced rectal cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>major histocompatibility complex class I (MHCI)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Melanoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metastasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metastatic colorectal cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microbiome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Microfluidics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microsatellite instability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>miRNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neutrophils</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NSCLC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PD-L1 expression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>platelets</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prostate cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prostate cancer (PCa)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RAD23B</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rovalpituzumab tesirine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rVAR2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>single-cell analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SLUG</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>small-cell lung carcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>solid cancers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Stem Cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>synaptophysin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>targeted therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thymidylate synthase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tumor biomarkers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tumor cell dissemination</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tumor stem cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tumor-initiating cells (TICs)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>xenograft models</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>The analysis of circulating tumor cells (CTCs) as a real-time liquid biopsy approach can be used to obtain new insights into metastasis biology, and as companion diagnostics to improve the stratification of therapies and to obtain insights into the therapy-induced selection of cancer cells. In this book, we will cover all the different facets of CTCs to assemble a huge corpus of knowledge on cancer dissemination: technologies for their enrichment, detection, and characterization; their analysis at the single-cell level; their journey as CTC microemboli; their clinical relevance; their biology with the epithelial-to-mesenchymal transition (EMT); their stem-cell properties; their potential to initiate metastasis at distant sites; their ex vivo expansion; and their escape from the immune system.<br/><br/>Listed by <a href="https://unglue.it/work/458726/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://encrypted.google.com/books?id=HsvaDwAAQBAJ&amp;printsec=frontcover&amp;img=1&amp;zoom=1</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>20200403</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/311295/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.575181.768882</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>768882</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Computational Approaches in Discovery &amp; Design of Antimicrobial Peptides</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Agostinho Antunes</PersonName><PersonNameInverted>Antunes, Agostinho</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Guillermin Agüero-Chapin</PersonName><PersonNameInverted>Agüero-Chapin, Guillermin</PersonNameInverted></Contributor><Contributor><SequenceNumber>3</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Yovani Marrero-Ponce</PersonName><PersonNameInverted>Marrero-Ponce, Yovani</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>abscess model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>allosteric inhibition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>AMP discovery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>amphipathic peptides</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>AMPs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>AMPs database</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anti-inflammatory</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antibacterial peptide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anticancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antimicrobial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antimicrobial peptide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antimicrobial peptides</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antimicrobial resistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antiviral</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Apicomplexan</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>artificial intelligence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bioactive peptides</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biofilms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biosynthetic gene clusters</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cathelicidins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cell-penetrating</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>centrality measure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chemical space network</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Chemistry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>complex network</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>complex networks</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cryptococcus neoformans</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cryptosporidiosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>10</SubjectSchemeIdentifier><SubjectCode>DES000000</SubjectCode><SubjectHeadingText>Design</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ergosterol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>evolutionary algorithms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>evolutionary and PPI algorithms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>FOF1-ATP synthase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Genome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genome mining</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gram staining-based target</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>group fusion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>high-performance liquid chromatography (HPLC)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>human peptidome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>in silico drug discovery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>LL-37</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Machine learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mass Spectrometry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>molecular descriptors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>motif discovery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>multifunctional</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>non-toxic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>penetratins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>peptide design</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>peptide library screening</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>proteogenomics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>redox system</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reference, information &amp; interdisciplinary subjects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Reptiles</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Research &amp; information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ROS metabolism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>secondary metabolites</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>similarity searching</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>skin model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>StarPep</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>starPep toolbox software</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Streptomyces</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>structure-based drug design</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>synthetic antimicrobial peptides</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>toxoplasmosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tumor-homing peptide</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Antimicrobial resistance remains a major concern in medicine, especially during the COVID-19 pandemic, where microbial infections were frequent complications. To combat drug-resistant pathogens, there has been a renewed interest in the use of antimicrobial peptides (AMPs). This reprint focuses on the in-silico approaches used for the rational discovery and design of AMPs. Such computational methodologies range from classical homology-based and machine-learning prediction algorithms to complex similarity networks and evolutionary algorithms that use models of sequence evolution. Furthermore, the reprint explores the improvement of high-throughput screening techniques in the discovery of AMPs from biological samples, which has also led to the evolution of computational approaches that aid in this biodiscovery process. The reprint contains original research and review papers, which serve as valuable references for researchers dedicated to peptide drug development.<br/><br/>Listed by <a href="https://unglue.it/work/575181/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/aa/b5/aab5f10b27fcf4654864bb89ec5fcb6c.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/407718/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.303705.433912</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>433912</IDValue></ProductIdentifier><ProductIdentifier><ProductIDType>03</ProductIDType><IDValue>9781846318290</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Contagion and Enclaves</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Nandini Bhattacharya</PersonName><PersonNameInverted>Bhattacharya, Nandini</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bengal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Colonialism &amp; Imperialism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Darjeeling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Darjeeling district</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dooars</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>10</SubjectSchemeIdentifier><SubjectCode>HIS000000</SubjectCode><SubjectHeadingText>History</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>10</SubjectSchemeIdentifier><SubjectCode>HIS017000</SubjectCode><SubjectHeadingText>History / Asia / India &amp; South Asia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>History: specific events &amp; topics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Humanities</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>India</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Kolkata</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>KUnlatched</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>postcolonial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Tea</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Terai</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::N History and Archaeology::NH History::NHT History: specific events and topics::NHTQ Colonialism and imperialism</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Colonialism created exclusive economic and segregatory social spaces for the exploitation and management of natural and human resources, in the form of plantations, ports, mining towns, hill stations, civil lines and new urban centres for Europeans. Contagion and Enclaves studies the social history of medicine within two intersecting enclaves in colonial India; the hill station of Darjeeling which incorporated the sanitarian and racial norms of the British Raj; and in the adjacent tea plantations of North Bengal, which produced tea for the global market. It establishes the vital link between medicine, the political economy and the social history of colonialism. It demonstrates that while enclaves were essential and distinctive sites of articulation of colonial power and economy, they were not isolated sites. The book shows that the critical aspect of the enclaves was in their interconnectedness; with other enclaves, with the global economy and international medical research.<br/><br/>Listed by <a href="https://unglue.it/work/303705/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/8b/bd/8bbdab6af67dfc2042006faad6e08d5f.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>Liverpool University Press</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>20121120</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/289266/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.303705.433913</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>433913</IDValue></ProductIdentifier><ProductIdentifier><ProductIDType>03</ProductIDType><IDValue>9781781386361</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Contagion and Enclaves</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Nandini Bhattacharya</PersonName><PersonNameInverted>Bhattacharya, Nandini</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bengal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Colonialism &amp; Imperialism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Darjeeling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Darjeeling district</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dooars</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>10</SubjectSchemeIdentifier><SubjectCode>HIS000000</SubjectCode><SubjectHeadingText>History</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>10</SubjectSchemeIdentifier><SubjectCode>HIS017000</SubjectCode><SubjectHeadingText>History / Asia / India &amp; South Asia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>History: specific events &amp; topics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Humanities</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>India</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Kolkata</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>KUnlatched</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>postcolonial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Tea</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Terai</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::N History and Archaeology::NH History::NHT History: specific events and topics::NHTQ Colonialism and imperialism</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Colonialism created exclusive economic and segregatory social spaces for the exploitation and management of natural and human resources, in the form of plantations, ports, mining towns, hill stations, civil lines and new urban centres for Europeans. Contagion and Enclaves studies the social history of medicine within two intersecting enclaves in colonial India; the hill station of Darjeeling which incorporated the sanitarian and racial norms of the British Raj; and in the adjacent tea plantations of North Bengal, which produced tea for the global market. It establishes the vital link between medicine, the political economy and the social history of colonialism. It demonstrates that while enclaves were essential and distinctive sites of articulation of colonial power and economy, they were not isolated sites. The book shows that the critical aspect of the enclaves was in their interconnectedness; with other enclaves, with the global economy and international medical research.<br/><br/>Listed by <a href="https://unglue.it/work/303705/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>Liverpool University Press</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>20121120</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/223928/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.580617.776628</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>776628</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>COVID-19 Vaccines</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Ibrokhim Y. Abdurakhmonov</PersonName><PersonNameInverted>Abdurakhmonov, Ibrokhim Y.</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clinical trials</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Coronavirus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Epidemiology &amp; medical statistics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Medicine: General Issues</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Public health &amp; preventive medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SARS-CoV-2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Tuberculosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>vaccination</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>COVID-19 Vaccines - Current State and Perspectives provides the reader with the latest overview and opinions on the current state of the art in COVID-19 vaccines, as well as future prospects. The challenges covered include novel vaccine development for the emerging variants of concern (VOCs), vaccine side-effects with real-world examples, population hesitancy, and country experiences with COVID-19 vaccine development, clinical trialing and mass vaccination. Chapters discuss new opinions and directions on the repurposing of existing traditional vaccines with a wide spectrum of action and new platforms for fast-tracked vaccine production and approvals.<br/><br/>Listed by <a href="https://unglue.it/work/580617/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/d2/43/d24375dc337eae9df8977773b5fb95f7.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>IntechOpen</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/414528/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.531761.710760</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>710760</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>COVID-19: Current Challenges and Future Perspectives</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Peter Leggat</PersonName><PersonNameInverted>Leggat, Peter</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>John Frean</PersonName><PersonNameInverted>Frean, John</PersonNameInverted></Contributor><Contributor><SequenceNumber>3</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Lucille Blumberg</PersonName><PersonNameInverted>Blumberg, Lucille</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Africa</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>alcohol-related liver disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antiretroviral therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Attitudes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bangladesh</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bowel perforation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Chagas Disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Chronic Kidney Disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cirrhosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clinical trials</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CMV</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cognitive bias</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>coinfections</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Control</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Coronavirus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COVID-19</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COVID-19 vaccines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cytokine release syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cytokine storm</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>D-Dimer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diagnostic reasoning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Differential Diagnosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>efficacy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>emergency</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>endemic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Environmental medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>EpiCollect5</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Epidemiology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Ethics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fecal calprotectin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>general practitioners</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Harare</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>health care workers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>health systems</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>healthcare personnel</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>healthcare worker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>healthcare workers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>heart transplant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hepatitis B and C</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HIV</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>IL-6 inhibitors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>impact</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>India</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Infection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Influenza</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ischemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kaletra</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Kenya</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Knowledge</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lilongwe</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lopinavir/ritonavir</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Malawi</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MDR-TB</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>medical doctor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MERS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mortality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nairobi</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>necrosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nepal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nonalcoholic steatohepatitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Operational research</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Other branches of medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>overview</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pandemic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pandemics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>perceptions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Philippines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plasmodium falciparum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>post-acute COVID-19 syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>preparedness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>presumptive tuberculosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Public Health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>real-time operational research</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>recurrence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>reinfection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>research capacity building</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>respiratory viruses</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rhinovirus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Safety</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SARS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SARS-CoV-1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SARS-CoV-2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>severe acute respiratory syndrome coronavirus 2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>severity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SORT IT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TB treatment outcomes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Thrombosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tocilizumab</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Training</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Tuberculosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Zimbabwe</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>On March 11, 2020, the World Health Organization declared COVID-19 a global pandemic and the disease now affects nearly every country and region. Caused by SARS-CoV-2, COVID-19 presents significant challenges to health systems and public health in both hemispheres as well as to the economies of each country. The morbidity and mortality due to infections caused by SARS-CoV-2 have been significant despite the short duration since its discovery and initially overwhelmed many hospitals and clinics. It influences everyone, and countermeasures have been dramatic in their impact on employment, social systems, and mental health. This Special Issue provides an avenue for authors from various disciplines to provide feedback on our responses and preparedness to COVID-19 globally as well as to disseminate critical information about the SARS-CoV-2 virus and the associated COVID-19 pandemic. It consists of 22 peer-reviewed papers that cover worldwide perspectives encompasses the following: Original articles about COVID-19 (including epidemiology, modelling, clinical data, treatment, prevention, countermeasures, impacts on tropical regions, response, and preparedness);Original articles about SARS-CoV-2 (microbiology, virology, transmission, pathology, and vaccinology);Perspectives about COVID-19 and SARS-CoV-2 (comparisons with past coronavirus outbreaks, impactful local initiatives, novel responses, and commentaries);Reviews on COVID-19 (based on systematic and narrative reviews);and Innovations (vaccine development, drug trials, and original countermeasures).<br/><br/>Listed by <a href="https://unglue.it/work/531761/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/4d/52/4d52c766c4d19b8fcd1c2f832e29cdbf.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2022</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/374848/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.511155.684862</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>684862</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E116</ProductFormDetail><ProductFormDetail>E101</ProductFormDetail><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Development of Humanized Mouse Models for Infectious Diseases and Cancer</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Moriya Tsuji</PersonName><PersonNameInverted>Tsuji, Moriya</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Ramesh Akkina</PersonName><PersonNameInverted>Akkina, Ramesh</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Clinical &amp; internal medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diseases &amp; disorders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>humanized mice for HIV</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>humanized mice in cancer research</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>humanized mice in infectious disease research</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immunology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>improved humanized mouse models</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>new humanized mouse models</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vaccines and therapeutics</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>While the traditional animal models contributed immensely to biomedical research there remain many knowledge gaps in translating the results from these to humans. In this context, humanized mice transplanted with functional human cells in a physiological setting offer many advantages in deriving pre-clinical data more akin to that seen in the natural human host. There have been many recent advances in the field that encompass derivation of new transgenic breeds of immunodeficient mice harboring human cytokines and HLA alleles that permit improved human cell engraftment and differentiation. The ability to generate humanized mice with a functional immune system together with human tissue transplantation such as a functional liver has now paved the way for new experimentation not previously feasible and is beginning to shed light on the complex picture of human pathophysiology and immunopathogenesis. Specifically, human specific pathogens such as HIV, hepatitis viruses and malaria parasites are being studied in these systems and important data on pathogen life cycles in human cells in vivo, viral latency and human specific immune responses are being gathered. In the hematology front, new data are emerging on graft versus host disease using these models. Patient derived xenograft models endowed with transplanted human immune cells are permitting evaluations of various immunotherapies and identification of specific drugs for cancer therapy. Pathogenesis and immune responses for deadly pathogens, such as Ebola and newly emerged viruses like Zika are also being studied, adding a new twist and generating new knowledge in the context of human target cells in an in vivo setting.<br/><br/>Listed by <a href="https://unglue.it/work/511155/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/0c/04/0c046fb4f084cf13b1e26fdaffcf6c2a.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>Frontiers Media SA</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2020</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">mobi file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/355132/</WebsiteLink></Website><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">epub file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/354089/</WebsiteLink></Website><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/354088/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.195550.291596</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>291596</IDValue></ProductIdentifier><ProductIdentifier><ProductIDType>03</ProductIDType><IDValue>9788575413944</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E101</ProductFormDetail><ProductFormDetail>E107</ProductFormDetail><ProductFormDetail>E116</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-SA</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-sa/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Doenças endêmicas: abordagens sociais, culturais e comportamentais</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Rita Barradas Barata</PersonName><PersonNameInverted>Barata, Rita Barradas</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Roberto Briceño-León</PersonName><PersonNameInverted>Briceño-León, Roberto</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>por</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Doença de chagas</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Doenças endêmicas</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Epidemiology &amp; medical statistics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Esquistossomose</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hanseníase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Medicine: General Issues</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Public health &amp; preventive medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RC109-216</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::M Medicine and Nursing::MB Medicine: general issues::MBN Public health and preventive medicine::MBNS Epidemiology and Medical statistics</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>No mundo, cerca de meio bilhão de pessoas sofrem de enfermidades parasitárias endêmicas. Na América Latina, ainda se convive com velhas endemias como esquistossomose, malária, leshmanioses e hanseníase. A solução? Construir, de maneira solidária, o campo da saúde coletiva. Reunindo artigos de 35 conceituados pesquisadores latino-americanos, Doenças Endêmicas aproxima as abordagens teórico-metodológicas das ciências sociais e da epidemiologia. Certamente será útil para todos os profissionais interessados em desenvolver estratégias alternativas na formulação, implementação e avaliação de programas de controle de endemias.<br/><br/>Listed by <a href="https://unglue.it/work/195550/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/de/cd/decdde527a2874bf851de7f688db2ad2.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>SciELO Books - Editora FIOCRUZ</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2000</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">epub file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/443449/</WebsiteLink></Website><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/443448/</WebsiteLink></Website><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">mobi file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/237852/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.139434.218007</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>218007</IDValue></ProductIdentifier><ProductIdentifier><ProductIDType>03</ProductIDType><IDValue>9783863950477</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Global Health</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Martin Kappas</PersonName><PersonNameInverted>Kappas, Martin</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Uwe Groß</PersonName><PersonNameInverted>Groß, Uwe</PersonNameInverted></Contributor><Contributor><SequenceNumber>3</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Dermot Kelleher</PersonName><PersonNameInverted>Kelleher, Dermot</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>ger</LanguageCode></Language><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Economics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Economics, finance, business &amp; management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gesundheit</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gesundheitsrisiken</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GIHN Goettingen International Health Network</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GIHN Göttingen International Health Network</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Global Environmental Change</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Health Economics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Health Risks</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Health systems &amp; services</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Maternal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Medicine: General Issues</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Personal &amp; public health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Public health &amp; preventive medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>10</SubjectSchemeIdentifier><SubjectCode>SCI000000</SubjectCode><SubjectHeadingText>Science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Social conditions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Viren</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Human, animal and plant health is a field of work which offers opportunities for inter- and trans-disciplinary research. The whole topic bridges the natural and social sciences. Today, in a world of global environmental change it is widely recognized that human socities and their wellbeing depend on a sustainable equilibrium of ecosystem services and the possibility of cultural adaption to global environmental change. The need to identify and quantify health risks related to global environmental change is now one of the most important challenges of humankind.Describing spatial (geographic, intra/inter-population) and temporal differences in health risks is an urgent task to understand societies' vulnerabilities and pritorities for interventions better. The Göttingen International Health Network (GIHN) is a research and teaching network in relation to this cross-cutting topic. The book provides a collection of articles which contribute to this issue of overriding importance and presents an overview of the GIHN launch event.<br/><br/>Listed by <a href="https://unglue.it/work/139434/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://encrypted.google.com/books?id=1YKXl3XyfzgC&amp;printsec=frontcover&amp;img=1&amp;zoom=1</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>Universitätsverlag Göttingen</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2012</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/294214/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.510600.684305</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>684305</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E116</ProductFormDetail><ProductFormDetail>E101</ProductFormDetail><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Immunity to Malaria and Vaccine Strategies</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Kevin N. Couper</PersonName><PersonNameInverted>Couper, Kevin N.</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Julius C. Hafalla</PersonName><PersonNameInverted>Hafalla, Julius C.</PersonNameInverted></Contributor><Contributor><SequenceNumber>3</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Noah S. Butler</PersonName><PersonNameInverted>Butler, Noah S.</PersonNameInverted></Contributor><Contributor><SequenceNumber>4</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Ashraful Haque</PersonName><PersonNameInverted>Haque, Ashraful</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>B cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Clinical &amp; internal medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dendritic Cells </SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diseases &amp; disorders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immunology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Plasmodium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>T cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>vaccination</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact<br/><br/>Listed by <a href="https://unglue.it/work/510600/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/64/cc/64ccf6920d95c722724b8ca8f33f145c.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>Frontiers Media SA</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2019</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">mobi file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/355456/</WebsiteLink></Website><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">epub file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/353228/</WebsiteLink></Website><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/353227/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.511275.684982</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>684982</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E116</ProductFormDetail><ProductFormDetail>E101</ProductFormDetail><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Innovative Therapeutic and Immunomodulatory Strategies for Protozoan Infections</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Jorge Enrique Gomez-Marin</PersonName><PersonNameInverted>Gomez-Marin, Jorge Enrique</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Kamal El Bissati</PersonName><PersonNameInverted>Bissati, Kamal El</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>artemisin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chimioinformatics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Clinical &amp; internal medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diseases &amp; disorders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Giardia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Immunomodulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Infectious &amp; contagious diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Plasmodium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>protozoa</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>protozoan</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>reverse vaccines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Science: general issues</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Toxoplasma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>toxoplasmosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Trypanosoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Vaccines</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact<br/><br/>Listed by <a href="https://unglue.it/work/511275/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/94/02/94026173bca15a5c61df01792d9a55cd.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>Frontiers Media SA</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2019</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">mobi file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/355052/</WebsiteLink></Website><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">epub file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/354271/</WebsiteLink></Website><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/354270/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.567492.759119</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>759119</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Insecticides for Mosquito Control: Strengthening the Evidence Base</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Rosemary S. Lees</PersonName><PersonNameInverted>Lees, Rosemary S.</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Aedes aegypti</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Aedes albopictus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anophèles</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anopheles gambiae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Anopheles mosquito</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>application technology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ATSB</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Attractive Targeted Sugar Bait (ATSB)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Attractive Toxic Sugar Bait (ATSB)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>automated identification</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bifenthrin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bio-efficacy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bioassay</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bioefficacy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bioinsecticide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bite-proof garment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>broflanilide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clothianidin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>convolutional neural network</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Culex pipiens</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Culex quinquefasciatus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cuticular resistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cytochrome P450s</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>deltamethrin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diagnostic bioassay</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>disease transmission</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dual active ingredients (dual-AI)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dual-AI ITN</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>durability monitoring</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>etofenprox</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fertility</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>host-seeking behavior</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>human arm</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>image classification</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>imidacloprid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insecticide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insecticide exposure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insecticide resistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insecticide resistance management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insecticide resistance management (IRM)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insecticide selection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insecticide treated nets</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insecticide-resistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insecticide-treated net (ITN)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insecticide-treated nets (ITN)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>interceptor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>interceptor G2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Iroquois</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>IRs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ITNs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kdr</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>laboratory screening</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>life tables</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Machine learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>malaria control</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>malaria vector</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>membrane</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>method development</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>method validation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mosquito</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mosquito control</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mosquito fitness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mosquito-borne disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mosquitoes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>natural compounds</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>non-insecticidal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>out-crossing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ovary development</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pathogen transmission</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PBO ITN</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>physical barrier</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phytochemical</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pirimiphos-methyl</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prallethrin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>product evaluation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Protection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pyrethroid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pyrethroid resistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pyrethroids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pyriproxyfen (PPF)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>quality control (QC)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rabbit</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reference, information &amp; interdisciplinary subjects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Research &amp; information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>resistance monitoring</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RNAi</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Saccharomyces cerevisiae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>side-effects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spatial treatment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>strain authentication</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>strain characterisation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>synergist ITN</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>textile</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thiacloprid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Vector control</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>WHO tube</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>WHO tunnel test</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Yeast</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>α-cypermethrin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>β-cyfluthrin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>λ-cyhalothrin</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>The eradication of vector-borne diseases is threatened by the limited range of available insecticides, leading, inevitably, to the development of resistance. This is particularly concerning for malaria control, which relies heavily on insecticide-treated nets (ITNs) and indoor residual sprays (IRS). New chemistries are being developed, and innovative deployment of insecticides may play a role in overcoming resistance, either through new types of tools or new means of distribution. A variety of novel product types and vector control strategies are under development and evaluation, which is to be celebrated, but a strong evidence base is needed to guide effective operational deployment decisions. Novel approaches should be supported by robust data collected using appropriate and validated methods to monitor efficacy, durability, and any emerging resistance. This reprint presents original research into developing and characterizing new vector control products, as well as understanding and monitoring insecticide resistance. Review articles explore the impact of insecticide resistance and offer guidance on insecticide choice in the face of pyrethroid resistance. Consensus methodologies are presented, in the form of standard operating procedures (SOPs) designed to be adopted and used to generate reproducible data that can be compared and interpreted across and between studies. It is hoped that this collection of articles offers inspiration and guidance on how consistent data can be generated to inform more effective development, evaluation, and use of new and existing vector control tools.<br/><br/>Listed by <a href="https://unglue.it/work/567492/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/f6/4b/f64bf0b9a8cb25e0a5a8cbe9b6aa14ab.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/407137/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.457541.619130</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>619130</IDValue></ProductIdentifier><ProductIdentifier><ProductIDType>03</ProductIDType><IDValue>9783039281145</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Iron as Therapeutic Targets in Human Diseases</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Paolo Arosio</PersonName><PersonNameInverted>Arosio, Paolo</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Maura Poli</PersonName><PersonNameInverted>Poli, Maura</PersonNameInverted></Contributor><Contributor><SequenceNumber>3</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Raffaella Gozzelino</PersonName><PersonNameInverted>Gozzelino, Raffaella</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>3-hydroxy-4-pyridinone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>acute kidney injury</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>acute lung injury</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adverse event profile</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Africa</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>age-related macular degeneration (AMD)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Alzheimer’s disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anaemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Anemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Anemia of chronic disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anemia of inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anti-hepcidin therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Antibacterial activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antitumor compound</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Bacteria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>binding ability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bioavailability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bioengineering</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>BMP/Smad</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bone homeostasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Brain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Brain Development</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiomyocyte</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cardiovascular Disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cataracts syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CD8+ T cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>central nurse macrophage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chaotropes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chelation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chelators</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Children</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chronic heart failure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Chronic Kidney Disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cinnamic acid derivatives</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cognition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>colorectal cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COPD</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cystic fibrosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cytokines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Developing countries</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Developmental</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>didox</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Drug delivery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>efficacy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>electron transfer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>erythroblastic islands</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>erythrophagocytosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Erythropoiesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fe2+-chelating activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ferritin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ferritinophagy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ferroportin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ferroptosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>FeSO4</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>flavin nucleotide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Flavonoids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fluorescent iron chelator</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fluorophore</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Friedreich Ataxia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genetic hemochromatosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Growth</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gut Microbiota</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>haem</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>haptoglobin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Heme</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>heme homeostasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>heme oxygenase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hemochromatosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hemolysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hemopexin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hemorrhage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hepcidin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hereditary hyperferritinemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hereditary hypoferritinemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HFE</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>histidine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hypoxia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Immunity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Indonesia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Infants</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Infection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammatory Bowel Disease (IBD)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>innate immunity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>interleukin-6</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intestinal inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intravenous iron</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Iron</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron absorption</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron chelation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron chelation therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Iron chelators</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Iron deficiency</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron deficiency anemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron delivery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron dextran</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron homeostasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron metabolism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron mobilization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron overload</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron processing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron regulatory proteins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron release</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron supplementation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron transporters</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron-carbohydrate complex</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Iron-sulfur</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>IV iron therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Kidney</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kinetics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Kupffer cell</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>labile iron</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lipid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Liver</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>low and middle income countries</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lung</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lung Diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lung infection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>M cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>macrophage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Macrophages </SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mek/Erk</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>membrane interactions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Metabolism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MHC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microbiome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mitochondria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mucosal immunity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>multifunctional iron chelators</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mycobacteria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NaFeEDTA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nanocage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nanotechnology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Natural history</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NBIA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NCOA4</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neonatal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neonatal period</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neurodegeneration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neurodegeneration with brain iron accumulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neurodegenerative disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neurodegenerative Diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroimmune responses</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroinflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neurophysiology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>non transferrin bound iron</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>non-haem iron</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>non-HFE</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>non-transferrin-bound iron (NTBI)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nutrient iron</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Obesity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral iron salts</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral iron therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>osteoblast</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>osteoclast</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>osteoporosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Oxidative Stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oxygen sensing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient blood management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>peritoneal dialysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pharmaceutical targets</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Phlebotomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pig</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pituitary</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Prevention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>protein binding</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pulmonary arterial hypertension</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pulmonary arterial smooth muscle cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>red pulp macrophage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>reducibility</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Retina</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Rheumatoid arthritis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rhodamine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RRM2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SCFA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>senescence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>serum biomarker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SLC40A1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SNC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Social Behavior</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>soybean seed ferritin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sucrosomial® iron</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>supplementation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>T lymphocytes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Tfr2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::P Mathematics and Science::PS Biology, life sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TNF</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tolerability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transferrin receptor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Trauma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Treatment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vascular calcification</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>venesections</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Iron is an essential element for almost all organisms, a cofactor playing a crucial role in a number of vital functions, including oxygen transport, DNA synthesis, and respiration. However, its ability to exchange electrons renders excess iron potentially toxic, since it is capable of catalyzing the formation of highly poisonous free radicals. As a consequence, iron homeostasis is tightly controlled by sophisticated mechanisms that have been partially elucidated. Because of its biological importance, numerous disorders have been recently linked to the deregulation of iron homeostasis, which include not only the typical disorders of iron overload and deficiency but also cancer and neurodegenerative diseases. This leads iron metabolism to become an interesting therapeutic target for novel pharmacological treatments against these diseases. Several therapies are currently under development for hematological disorders, while other are being considered for different pathologies. The therapeutic targeting under study includes the hepcidin/ferroportin axis for the regulation of systemic iron homeostasis, complex cytosolic machineries for the regulation of the intracellular iron status and its association with oxidative damage, and reagents exploiting proteins of iron metabolism such as ferritin and transferrin receptor. A promising potential target is a recently described form of programmed cell death named ferroptosis, in which the role of iron is essential but not completely clarified. This Special Issue has the aim to summarize the state-of-the-art, and the latest findings published in the iron field, as well as to elucidate future directions.<br/><br/>Listed by <a href="https://unglue.it/work/457541/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://encrypted.google.com/books?id=pn7PDwAAQBAJ&amp;printsec=frontcover&amp;img=1&amp;zoom=1</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>20200211</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/465762/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.457540.619128</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>619128</IDValue></ProductIdentifier><ProductIdentifier><ProductIDType>03</ProductIDType><IDValue>9783039280827</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Iron as Therapeutic Targets in Human Diseases</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Paolo Arosio</PersonName><PersonNameInverted>Arosio, Paolo</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Maura Poli</PersonName><PersonNameInverted>Poli, Maura</PersonNameInverted></Contributor><Contributor><SequenceNumber>3</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Raffaella Gozzelino</PersonName><PersonNameInverted>Gozzelino, Raffaella</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>3-hydroxy-4-pyridinone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>acute kidney injury</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>acute lung injury</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adverse event profile</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Africa</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>age-related macular degeneration (AMD)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Alzheimer’s disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anaemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Anemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Anemia of chronic disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anemia of inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anti-hepcidin therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Antibacterial activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antitumor compound</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Bacteria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>binding ability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bioavailability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bioengineering</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>BMP/Smad</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bone homeostasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Brain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Brain Development</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiomyocyte</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cardiovascular Disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cataracts syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CD8+ T cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>central nurse macrophage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chaotropes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chelation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chelators</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Children</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chronic heart failure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Chronic Kidney Disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cinnamic acid derivatives</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cognition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>colorectal cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COPD</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cystic fibrosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cytokines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Developing countries</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Developmental</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>didox</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Drug delivery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>efficacy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>electron transfer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>erythroblastic islands</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>erythrophagocytosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Erythropoiesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fe2+-chelating activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ferritin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ferritinophagy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ferroportin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ferroptosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>FeSO4</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>flavin nucleotide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Flavonoids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fluorescent iron chelator</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fluorophore</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Friedreich Ataxia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genetic hemochromatosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Growth</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gut Microbiota</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>haem</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>haptoglobin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Heme</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>heme homeostasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>heme oxygenase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hemochromatosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hemolysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hemopexin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hemorrhage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hepcidin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hereditary hyperferritinemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hereditary hypoferritinemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HFE</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>histidine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hypoxia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Immunity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Indonesia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Infants</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Infection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammatory Bowel Disease (IBD)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>innate immunity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>interleukin-6</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intestinal inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intravenous iron</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Iron</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron absorption</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron chelation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron chelation therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Iron chelators</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Iron deficiency</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron deficiency anemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron delivery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron dextran</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron homeostasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron metabolism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron mobilization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron overload</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron processing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron regulatory proteins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron release</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron supplementation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron transporters</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron-carbohydrate complex</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Iron-sulfur</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>IV iron therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Kidney</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kinetics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Kupffer cell</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>labile iron</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lipid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Liver</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>low and middle income countries</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lung</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lung Diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lung infection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>M cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>macrophage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Macrophages </SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mek/Erk</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>membrane interactions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Metabolism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MHC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microbiome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mitochondria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mucosal immunity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>multifunctional iron chelators</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mycobacteria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NaFeEDTA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nanocage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nanotechnology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Natural history</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NBIA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NCOA4</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neonatal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neonatal period</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neurodegeneration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neurodegeneration with brain iron accumulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neurodegenerative disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neurodegenerative Diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroimmune responses</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroinflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neurophysiology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>non transferrin bound iron</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>non-haem iron</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>non-HFE</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>non-transferrin-bound iron (NTBI)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nutrient iron</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Obesity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral iron salts</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral iron therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>osteoblast</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>osteoclast</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>osteoporosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Oxidative Stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oxygen sensing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient blood management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>peritoneal dialysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pharmaceutical targets</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Phlebotomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pig</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pituitary</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Prevention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>protein binding</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pulmonary arterial hypertension</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pulmonary arterial smooth muscle cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>red pulp macrophage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>reducibility</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Retina</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Rheumatoid arthritis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rhodamine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RRM2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SCFA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>senescence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>serum biomarker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SLC40A1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SNC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Social Behavior</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>soybean seed ferritin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sucrosomial® iron</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>supplementation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>T lymphocytes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Tfr2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::P Mathematics and Science::PS Biology, life sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TNF</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tolerability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transferrin receptor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Trauma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Treatment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vascular calcification</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>venesections</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Iron is an essential element for almost all organisms, a cofactor playing a crucial role in a number of vital functions, including oxygen transport, DNA synthesis, and respiration. However, its ability to exchange electrons renders excess iron potentially toxic, since it is capable of catalyzing the formation of highly poisonous free radicals. As a consequence, iron homeostasis is tightly controlled by sophisticated mechanisms that have been partially elucidated. Because of its biological importance, numerous disorders have been recently linked to the deregulation of iron homeostasis, which include not only the typical disorders of iron overload and deficiency but also cancer and neurodegenerative diseases. This leads iron metabolism to become an interesting therapeutic target for novel pharmacological treatments against these diseases. Several therapies are currently under development for hematological disorders, while other are being considered for different pathologies. The therapeutic targeting under study includes the hepcidin/ferroportin axis for the regulation of systemic iron homeostasis, complex cytosolic machineries for the regulation of the intracellular iron status and its association with oxidative damage, and reagents exploiting proteins of iron metabolism such as ferritin and transferrin receptor. A promising potential target is a recently described form of programmed cell death named ferroptosis, in which the role of iron is essential but not completely clarified. This Special Issue has the aim to summarize the state-of-the-art, and the latest findings published in the iron field, as well as to elucidate future directions.<br/><br/>Listed by <a href="https://unglue.it/work/457540/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://encrypted.google.com/books?id=PH7PDwAAQBAJ&amp;printsec=frontcover&amp;img=1&amp;zoom=1</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>20200211</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/465711/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.400230.545493</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>545493</IDValue></ProductIdentifier><ProductIdentifier><ProductIDType>03</ProductIDType><IDValue>9783038977803</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Isolation and Structure Elucidation of Bioactive Compounds (Dedicated to the memory of the late Professor Charles D. Hufford)</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Muhammad Ilias</PersonName><PersonNameInverted>Ilias, Muhammad</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Charles L. Cantrell</PersonName><PersonNameInverted>Cantrell, Charles L.</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>(E)-8(17)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>(E)-8(17),12-labdadiene-15,16-dial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>12-labdadiene-15</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>13(S)-hydroxyatisenoic acid derivative</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>16-dial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>acacetin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>acacetin 7-methyl ether</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>acylphloroglucinol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>aldose reductase inhibitor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>alkaloids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>amphotericin B</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>analgesic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anti-inflammatory</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anti-leishmanial activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antibacterial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antimalarial activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antimicrobial resistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antioxidant activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antipyretic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antitrypanosomal activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>aromatic compounds</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Arthrinium sp.</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>augustine N-oxide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Baccharis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biological activities</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>buphanisine N-oxide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>C-26-oxidation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>C-27-oxidation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiomyogenesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>carotenoids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>channel catfish</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chromone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cochlospermaceae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cochlospermum vitifolium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>columnaris disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>coumarinolignans</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Crinum amabile</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cryptococcosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cryptococcus neoformans</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cunninghamella echinulata</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cytochalasins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cytotoxic activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cytotoxicity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dietary supplement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diterpene glycosides</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diterpenes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DNA barcoding</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>endophytic fungi</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>factor VII</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>factor X</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Flavobacterium columnare</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Flavonoids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>flavonoids glycosides</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fluconazole</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fusidic acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gastro-resistant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GC/MS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HepG2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>herbal medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hop prenylflavanone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HPLC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HPLC-ESI-IT-MS/MS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Il-8</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iNOS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insecticidal activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iso-stevioside X-ray structure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>isolation and elucidation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>isoxanthohumol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Jatropha pelargoniifolia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>jenipapo</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Leishmania donovani</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lignans</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Litsea cubeba</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>liver activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>maleimides</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>methicillin resistant Staphylococcus aureus (MRSA)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microbial transformation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microparticles</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Microscopy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mitracarpus scaber Zucc.</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>molecular docking</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Molecular Dynamics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>monoamine oxidase-A</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>monoamine oxidase-B</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Morus alba L.</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MS/MS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>multi-drug resistant (MDR)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>muscadine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Natural Products</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nemania</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neurological disorder</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroprotective agent</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NF-?B</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Obesity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pancreatic Cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pentalogin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phlorogluciniol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phytotoxicity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plant pathogenic and endophytic fungi</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>polyketide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prosopilosidine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Prosopis glandulosa</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pyranoanthocyanin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rebaudioside A isomers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>resveratrol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Rubiaceae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SAR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sesterterpene</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sterols</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Stevia rebaudiana</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>stilbenes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>terpenes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::P Mathematics and Science::PN Chemistry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Thrombosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Torreya taxifolia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Turnera diffusa</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vasculogenesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Xylariaceae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>zerumbol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Zingiber monatnum</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>We are very pleased to introduce the Book Version of our Special Issue in Molecules dedicated to the memory of the late Professor Dr. Charles D. Hufford. The issue has been a huge success, with 22 full-length peer-reviewed papers and a tribute by Professor Alice M.Clark. Authors, reviewers, and collaborators from many countries across the worldhave contributed to this endeavour, and we are truly grateful to all. This Special Issue isrepresentative of the broad impact that “Charlie” had on the field of bioactive naturalproducts. This Special Issue comprises papers from Professor Hufford’s former students,colleagues, and collaborators throughout the world who have utilized a wide array ofstate-of-the-art techniques to examine diverse natural sources to isolate and identify avariety of natural products with a wide spectrum of biological activities, including somenew microbial transformations and insights into bioactive molecules. Many new bioactive compounds are described and reported here for the first time. Bioactivities reportedinclude cytotoxicity, antimicrobial activity, anti-inflammatory activity, antileishmanialactivity, antitrypanosomal activity, antimalarial activity, analgesic activity, and beneficialliver activities, just to name a few. This Special Issue will undoubtedly have a lasting impact on the field of bioactive natural products, as exemplified by the career of Dr. Hufford.Lastly, without the timely and outstanding contributions from all of you, this Special Issue would not have been possible. We thank you all very much for your contributions and your time devoted to this Special Issue in memory of a special person. Finally, we express ourgratitude and thanks to the journal Molecules and their excellent team of expert reviewers for giving us the support and opportunity to make this Special Issue a huge success!<br/><br/>Listed by <a href="https://unglue.it/work/400230/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/d7/a7/d7a779ac56033244522101405f31ab2d.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>20190411</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/465840/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.393374.536600</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>536600</IDValue></ProductIdentifier><ProductIdentifier><ProductIDType>03</ProductIDType><IDValue>9782889455270</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E116</ProductFormDetail><ProductFormDetail>E101</ProductFormDetail><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Macromolecular Structure Underlying Recognition in Innate Immunity</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Uttara SenGupta</PersonName><PersonNameInverted>SenGupta, Uttara</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Uday Kishore</PersonName><PersonNameInverted>Kishore, Uday</PersonNameInverted></Contributor><Contributor><SequenceNumber>3</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Maha Ahmed Al-Mozaini</PersonName><PersonNameInverted>Al-Mozaini, Maha Ahmed</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>complement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HIV-1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Host-Pathogen Interactions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>innate immunity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pattern recognition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>protein-protein interaction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>zebrafish model system</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Immune molecules have evolved to distinguish “self “molecules from “non-self”, “altered self” and “danger” molecules. Recognition is mediated via interactions between pattern recognition receptor molecules (PPRs) and their ligands, which include hydrophobic and electrostatic interactions between amino acid residues on the PPRs and uncharged or charged groups on amino acid residues, sugar rings or DNA/RNA molecules. Recognition in innate immunity range from cases (C1q, mannin-binding protein etc) where recognition is orchestrated by interaction between many ligands with one receptor molecule, and density of interaction is necessary for strong specific recognition, distinct from weak non-specific binding, and cases such as TLRs and NLRs where recognition involves complexation of single receptor and ligand, followed by oligomerisation of the receptor molecule. The majority of PPR molecules bind and recognise a wide variety of ligands, e.g TLR4 recognises LPS (gram negative bacteria), Lipotechoic acid (gram positive bacteria), heat shock protein hsp60, respiratory syncytial virus fusion protein etc, molecules that are structurally dissimilar to each other. This indicates considerable flexibility in their binding domains (amino acid residue variations) and modes (hydrophobic and charged, direct or mediated via an adaptor molecule). However, in many cases there is a dearth of structural and molecular data available, required to delineate the mechanism of ligand binding underlining recognition in pathogen receptors in innate immunity. Insights into requirements of conformation, charge, surface etc in the recognition and function of innate immunity receptors and their activation pathways, based on current data can suggest valuable avenues for future work. <br/><br/>Listed by <a href="https://unglue.it/work/393374/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/72/4d/724d0968f714d97905d255e0e7c42f9b.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>Frontiers Media SA</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>20180709</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">mobi file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/269685/</WebsiteLink></Website><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">epub file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/267711/</WebsiteLink></Website><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/267710/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.390210.532449</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>532449</IDValue></ProductIdentifier><ProductIdentifier><ProductIDType>03</ProductIDType><IDValue>9781107172364</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Malarial Subjects</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Rohan Deb Roy</PersonName><PersonNameInverted>Roy, Rohan Deb</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cinchona</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>history of medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Medicine: General Issues</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>nineteenth century</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Presidencies and provinces of British India</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Quinine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::M Medicine and Nursing::MB Medicine: general issues::MBX History of medicine</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Malaria was considered one of the most widespread disease-causing entities in the nineteenth century. It was associated with a variety of frailties far beyond fevers, ranging from idiocy to impotence. And yet, it was not a self-contained category. The reconsolidation of malaria as a diagnostic category during this period happened within a wider context in which cinchona plants and their most valuable extract, quinine, were reinforced as objects of natural knowledge and social control. In India, the exigencies and apparatuses of British imperial rule occasioned the close interactions between these histories. In the process, British imperial rule became entangled with a network of nonhumans that included, apart from cinchona plants and the drug quinine, a range of objects described as malarial, as well as mosquitoes. Malarial Subjects explores this history of the co-constitution of a cure and disease, of British colonial rule and nonhumans, and of science, medicine and empire. This title is also available as Open Access.<br/><br/>Listed by <a href="https://unglue.it/work/390210/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/e0/54/e054f5bc81afeee7fa01c6ae0a89ba08.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>Cambridge University Press</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>20170930</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/293944/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.492199.659988</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>659988</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Marine Bioactive Natural Product Studies—A Southern Hemisphere Perspective</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Sylvia Urban</PersonName><PersonNameInverted>Urban, Sylvia</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Alcyoniidae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anticancer activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antiplasmodial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Aplidium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Apoptosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ascidian</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bioactive compounds</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bioactivity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biosynthesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bisindole alkaloids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>brominated secondary metabolites</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cell Death</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cembrane</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cephalostatin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>choline ester</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cnemidocarpa stolonifera</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>conotoxins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>crystal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cytotoxicity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diterpene</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>docking</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Echinodermata</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ESI</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>farnesyltransferase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>free energy perturbation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HIF-1α</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>holothurian</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HPCPC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immunofluorescence assay</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>indole</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Ion Channels</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Jurkat</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lobane</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MALDI</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mandelalide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>marine invertebrate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mass Spectrometry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>methicillin resistant Staphylococcus aureus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Molecular Dynamics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MRSA PK</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>natural product scaffold</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>p42/p44 MAPK</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PC3 cell line</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PI3K/AKT/mTOR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plasmodium falciparum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>potential of mean force</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>regioisomer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>salternamide A (SA)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>saponins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sea cucumber</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ShK toxin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sinularia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>STAT3</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>structure elucidation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Synthesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>taurine amide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thiaplakortone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thiaplidiaquinone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thiazinoquinone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tricyclic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>triterpene glycosides</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>viscera</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>X-ray</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>The search for bioactive secondary metabolites from marine organisms has been an active area of research since the 1950s. The distinct biodiversity of the marine environment has afforded a vast array of unique secondary metabolites, many of which possess potent biological activities. This Special Issue of Marine Drugs will highlight recent bioactive marine natural product studies conducted by southern hemisphere scientists on an array of marine organisms.<br/><br/>Listed by <a href="https://unglue.it/work/492199/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2020</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/382317/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.557699.746751</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>746751</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Marine Glycomics</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Yuki Fujii</PersonName><PersonNameInverted>Fujii, Yuki</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Marco Gerdol</PersonName><PersonNameInverted>Gerdol, Marco</PersonNameInverted></Contributor><Contributor><SequenceNumber>3</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Yasuhiro Ozeki</PersonName><PersonNameInverted>Ozeki, Yasuhiro</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>accumulation of carbohydrates</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Acropora tenuis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Alexandrium catenella</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Antibacterial activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anticancer activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anticoagulant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anticoagulant activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antifungal activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antiparasitic activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antiviral response</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Aplysia kurodai</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Apoptosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Arthrospira platensis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bacterial exopolysaccharides</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bioactive properties</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bioflocculanting activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biohydrogen</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biology, Life Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bivalve mollusk</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>C-type lectins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>C1q domain-containing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>C1q domain-containing proteins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chemoattraction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Chlorella vulgaris</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>contact activation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>coral</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cryptosporidiosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dunaliella salina</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Ehrlich ascites carcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fucoidan</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fucosylated chondroitin sulfate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fucosylated glycosaminoglycan</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>galectins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>growth rate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>harmful algal bloom-forming dinoflagellate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hypotension</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>innate immunity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>interferon</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>interstitial compartment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lectin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lectin-like</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>leishmaniasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mameliella alba</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>marine hydrobionts</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>marine worms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microalgae growth-promoting bacterium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microbe-associated molecular patterns</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oncolytic vaccinia virus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral administration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pattern recognition receptor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pattern Recognition Receptors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Peptides</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>platelet aggregation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>polysaccharides</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>protozoa</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pulmonary embolism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reference, information &amp; interdisciplinary subjects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Research &amp; information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rotifera</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Schistosomiasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sipunculids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sulfated fucan</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sulfated fucose-rich polysaccharides</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sulfated polysaccharides</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>trichomoniasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>trypanosomiasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>white-spotted charr lectin</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Marine creatures are rich sources of glycoconjugate-containing glycans and have diversified structures. The advance of genomics has provided a valuable clue for their production and developments. This information will encourage breeding and engineering functional polysaccharides with slime ingredients in algae. These glycans will have the potential for applications to antioxidant, anticancer, and antimicrobial drugs in addition to health supplements and cosmetics. The combination of both biochemical and transcriptome approaches of marine creatures will lead to the opportunity to discover new activities of proteins such as glycan-relating enzymes and lectins. These proteins will also be used for experimental and medical purposes, such as diagnostics and trial studies. The topic of marine glycomics is also focusing on understanding the physiological properties of marine creatures, such as body defense against pathogens and cancers. In the competitions for natural selection, living creatures have evolved both their glycans and their recognition. They have primitive systems of immunity, and few of their mechanisms are closely related to glycans. If we are able to describe the accumulation of data of glycans of creatures living in the seashore and the oceans, we may be able to anticipate a time when we can talk about the ecosystem with glycans. That knowledge will be useful for the development of drugs that cure our diseases and for an understanding of living systems in addition to the preservation of living environments.<br/><br/>Listed by <a href="https://unglue.it/work/557699/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/a1/3f/a13f8f6c85f757d515b3db95e40d2a7f.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2022</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/394377/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.525621.703424</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>703424</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Micro/Nano Devices for Blood Analysis, Volume II</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Rui A. Lima</PersonName><PersonNameInverted>Lima, Rui A.</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Graça Minas</PersonName><PersonNameInverted>Minas, Graça</PersonNameInverted></Contributor><Contributor><SequenceNumber>3</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Susana Catarino</PersonName><PersonNameInverted>Catarino, Susana</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>3D model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>3D printing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>air compliance effect</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>air-compressed syringe (ACS)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>automatic methods</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomicrofluidics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>blood cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>blood flow</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>blood molecules</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>blood plasma filtration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>blood velocity fields</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>blood viscoelasticity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>blood viscosity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chip extract</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>coflowing streams</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>colorectal cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>composite molding</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>crossover frequency</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diagnostics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dielectric spectra</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dielectrophoresis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Drug Screening</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Economics, finance, business &amp; management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>electrophysiological properties</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Erythrocyte sedimentation rate (ESR)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fourier transform infrared (FTIR) spectroscopy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>functional group</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Image analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Industry &amp; industrial studies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Information technology industries</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>interface</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>interface in co-flowing streams</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lab-on-a-chip</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>linear differential equation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>manual methods</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Media, information &amp; communication industries</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>micro-nano structure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>micro-particle image velocimetry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microfluidic device</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Microfluidics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>optical filters</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>particle tracking</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient-derived organoids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RBC aggregation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>red blood cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>reflectance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>small caliber blood vessel</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spectrophotometry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>T-shaped microfluidic channel</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TFCalc</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tissue repair</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>two approximate factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>viscoelasticity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>wake or recirculation formation</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>The development of micro- and nanodevices for blood analysis continues to be a growing interdisciplinary subject that demands the careful integration of different research fields. Following the success of the book “Micro/Nano Devices for Blood Analysis”, we invited more authors from the scientific community to participate in and submit their research for a second volume. Researchers from different areas and backgrounds cooperated actively and submitted high-quality research, focusing on the latest advances and challenges in micro- and nanodevices for diagnostics and blood analysis; micro- and nanofluidics; technologies for flow visualization and diagnosis; biochips, organ-on-a-chip and lab-on-a-chip devices; and their applications to research and industry.<br/><br/>Listed by <a href="https://unglue.it/work/525621/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/fa/a4/faa45536752b7376b9fc9e670e1292ce.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2022</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/369330/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.458775.620670</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>620670</IDValue></ProductIdentifier><ProductIdentifier><ProductIDType>03</ProductIDType><IDValue>9783039287468</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Natural Products and Drug Discovery</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Pinarosa Avato</PersonName><PersonNameInverted>Avato, Pinarosa</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>2?</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>2?,4?-dihydroxy-6?-methoxy-3?,5?-dimethylchalcone (DMC)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>4?-dihydroxy-6?-methoxy-3?</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>5?-dimethylchalcone (DMC)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ACE inhibitory peptide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>acetylated astragalosides</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Aging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Angiogenesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anti-inflammatory activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antihypertensive</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antimicrobial agents</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antimicrobial resistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antinociceptive</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antioxidant activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>artemisinin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Astragalus boeticus L.</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bacopa monnieri</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bioactive peptides</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bioactivities of natural products</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biotechnology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>C-glycoside</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Ca2+</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardamonin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cardiovascular Disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>celastrol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cerebellum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chemical derivatization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chemosystematics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chromatography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>circular dichroism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cleistocalyx operculatus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Cuba</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cytokines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cytotoxic activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cytotoxicity-guided</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dasycladus vermicularis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dementia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>devil’s claw</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diabetic neuropathy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dihydrochalcones</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dryopteris fragrans</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Eruca sativa</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ESI-MS/MS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fabaceae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fideloside</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>flavonoid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Flavonoids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>FSE</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glucoerucin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Glucosinolates</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GLUT4</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Glutamate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>growth inhibitory activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>H2S</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Harpagophytum procumbens</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>harpagoside</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HPLC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HPLC-ESI-microTOF-Q-MS/MS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>human colon cancer cell lines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Humulus lupulus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hypertension</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immuno-regulation activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Imperata cylindrica</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>isoflavones</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>isolation and quantification</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ketamine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Kv7 potassium channels</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>L6 cell</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lamiales</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>LC-MS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Leea indica</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Leishmania mexicana mexicana</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>marine peptides</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Marine resources</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mass Spectrometry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metabolomics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>methicillin-resistant Staphylococcus aureus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>migration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>molecular network</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>multivariate data analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NADPH oxidases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Natural Products</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuropathic pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NMR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Opioid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Orobanchaceae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Orobanche s.l.</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Oxidative Stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PANC-1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phenolic derivatives</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phenolics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phenylethanoid glycosides</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phenylpropanoid glycosides</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Phyllanthus chamacristoides</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Phyllanthus orbicularis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Physcomitrella patens</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pPancreatic cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prenylated phenolic compounds</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>proanthocyanidins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>proliferation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>psychosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>secondary metabolites</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sesquiterpenoids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>siphonous green algae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spagyric tincture</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spectroscopic analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Stereochemistry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sulfated coumarins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>synergy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>T2DM</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>terpenes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>terpenoids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::P Mathematics and Science::PS Biology, life sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Traditional medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Trifolium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TRPV1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Trypanosoma brucei brucei</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Zebrafish</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Natural products hold a prominent position in the current discovery and development of drugs and have diverse indications for both human and animal health. Plants, in particular, play a leading role as a source of specialized metabolites with medical effects. Other organisms, such as marine and terrestrial animals and microorganisms, produce very important drug candidate molecules. Specialized metabolites from these varied natural sources can be used directly as bioactive compounds or drug precursors. In addition, due to their broad chemical diversity, they can act as drug prototypes and/or be used as pharmacological tools for different targets. Some examples of natural metabolites that have been developed into useful medical drug are cardiotonic digoxin from Digitalis sp., antimalarial artemisinin from Artemisia annua, anti-cancer taxol from Taxus sp., or podophyllotoxin from Podophyllum peltatum, which served as a synthetic model for the anti-cancer etoposide. The study of natural products is still attracting great scientific attention and their current importance, as a valuable lead for drug discovery, is undebatable. I cordially invite authors to contribute original articles, as well as survey articles, that give the readers of Molecules **MOLECULES NEEDS TO BE ITALICIZED** updated and new perspectives on natural products in drug discovery, including but not limited to natural sources, identification and separation of bioactive phytochemicals, standardization, new biological targets, pre-clinical and clinical trials, pharmacological effects/side effects, and bioassays.<br/><br/>Listed by <a href="https://unglue.it/work/458775/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://encrypted.google.com/books?id=Ii3eDwAAQBAJ&amp;printsec=frontcover&amp;img=1&amp;zoom=1</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>20200422</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/466042/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.492079.659868</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>659868</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Neutrophil Extracellular Traps</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Hans-Joachim Anders</PersonName><PersonNameInverted>Anders, Hans-Joachim</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Shrikant R. Mulay</PersonName><PersonNameInverted>Mulay, Shrikant R.</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adults</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Alzheimer’s disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>autoantigens</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Autoimmune Diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Autoimmunity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Borrelia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Brain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>brain–blood barrier</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Candida albicans</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>carbon tetrachloride</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cardiovascular Disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cathelicidin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Central nervous system</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cerebrospinal fluid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Chemokines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Children</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>complement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Coronavirus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cytokines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>equine recurrent uveitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>farnesol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fibrinogen</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>G-CSF</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>head-and-neck cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hemozoin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>horse</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>IL-1β</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Infection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>innate immunity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ischemic stroke</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Liver Injury</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>meningitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MERS-CoV</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metastasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Multiple Sclerosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>myeloperoxidase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>necroinflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NETosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NETs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neurons</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neutrophil extracellular trap</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neutrophil Extracellular Traps</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neutrophil extracellular traps (NETs)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neutrophil functions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neutrophils</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neutrophils extracellular traps</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NLRP3 inflammasome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Obesity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Ophthalmology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>periodontitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Plasma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>platelet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Quorum Sensing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SARS-CoV-2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Thrombosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>virus</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Neutrophils regulate immune responses during homeostasis as well as disease pathogenesis. Especially, the neutrophils extracellular traps largely contribute to necroinflammation. This book highlights the role of neutrophils and neutrophils extracellular traps in various sterile and non-sterile, acute and chronic inflammatory conditions affecting both human and animal health.<br/><br/>Listed by <a href="https://unglue.it/work/492079/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2020</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/382201/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.574909.768609</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>768609</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>New Wars and Old Plagues</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Katherine Hirschfeld</PersonName><PersonNameInverted>Hirschfeld, Katherine</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Kirsten de Beurs</PersonName><PersonNameInverted>Beurs, Kirsten de</PersonNameInverted></Contributor><Contributor><SequenceNumber>3</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Brad Brayfield</PersonName><PersonNameInverted>Brayfield, Brad</PersonNameInverted></Contributor><Contributor><SequenceNumber>4</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Ani Melkonyan-Gottschalk</PersonName><PersonNameInverted>Melkonyan-Gottschalk, Ani</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>anthropology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Armed Conflict</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biology, Life Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>caucasus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>disease ecology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>emerging infectious diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Geography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>10</SubjectSchemeIdentifier><SubjectCode>HIS000000</SubjectCode><SubjectHeadingText>History</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Human biology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Human geography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Humanities</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>International relations</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Karabakh</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Medical anthropology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Medical geography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Medicine: General Issues</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>non-state actors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Politics &amp; government</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Post-Soviet history</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Public health &amp; preventive medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Regional &amp; national history</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Remote sensing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Society &amp; Social Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sociology &amp; anthropology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::J Society and Social Sciences::JH Sociology and anthropology::JHM Anthropology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::J Society and Social Sciences::JP Politics and government::JPS International relations</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::M Medicine and Nursing::MB Medicine: general issues::MBN Public health and preventive medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::N History and Archaeology::NH History::NHB General and world history</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSX Human biology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Warfare</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This Open Access book uses Mary Kaldor’s concept of “New Wars” to explore how ethnic conflict reshaped the social and environmental landscape of the Southern Caucuses following the collapse of the Soviet Union. It relies on remote sensing data and qualitative historical research to explore how armed conflict between non-state actors generated the region’s largest epidemic of P. vivax malaria since the 1960s. This book is an important addition to the literature on the Karabakh conflict and conflict studies more broadly because the infectious disease outbreaks associated with warfare often kill more people than the armed conflicts themselves. Warfare itself has also changed dramatically since the collapse of the USSR, and the Karabakh conflict provides an excellent case study of the way “New Wars” transform the natural and social environment to facilitate outbreaks of preventable disease. This extended case study will be useful to researchers from a variety of academic disciplines, including medical anthropology, geography, conflict studies, disease ecology, global health and public health. It also reveals the fragility of twentieth century malaria control in temperate regions and will assist in predictive modeling for future outbreaks.<br/><br/>Listed by <a href="https://unglue.it/work/574909/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/6c/8e/6c8e060e44430c510db43e142f1232ac.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>Springer Nature</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/409549/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.455786.616734</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>616734</IDValue></ProductIdentifier><ProductIdentifier><ProductIDType>03</ProductIDType><IDValue>9783039216147</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Newborn Screening for Sickle Cell Disease and other Haemoglobinopathies</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Stephan Lobitz</PersonName><PersonNameInverted>Lobitz, Stephan</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Jacques Elion</PersonName><PersonNameInverted>Elion, Jacques</PersonNameInverted></Contributor><Contributor><SequenceNumber>3</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Raffaella Colombatti</PersonName><PersonNameInverted>Colombatti, Raffaella</PersonNameInverted></Contributor><Contributor><SequenceNumber>4</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Elena Cela</PersonName><PersonNameInverted>Cela, Elena</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>(recommended) screening panel</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>?-globin gene</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>acute chest syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anaemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>automated HPLC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>birth prevalence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bone marrow transplant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>burden of disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>capillary electrophoresis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>caribbean</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Chemistry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cord blood</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diagnostics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>end-organ damage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>foetal haemoglobin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>G6PD deficiency</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gene therapy for haemoglobinopathies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glucose-6-phosphate dehydrogenase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Guthrie spots</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>haemolysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>harmonisation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Health Policy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hemoglobin pattern</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hemoglobinopathies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hemoglobinopathy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>high performance liquid chromatography (HPLC)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HPLC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hydroxyurea/hydroxycarbamide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>IEF</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>implementation science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>India</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Kaduna State</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>laboratory methods</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MALDI-TOF</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mass Spectrometry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Methods</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neonatal screening</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neonatal screening program</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>newborn</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>newborn screening</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>newborn screening)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nigeria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>non-tribal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pathophysiology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Patient advocacy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient organisations</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient representatives</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Plasmodium vivax</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>point-of-care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Policy Making</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Prevention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>public health engagement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Registry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>screening</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>service users</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sickle cell and thalassaemia screening programme</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sickle cell disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sickle cell disease (SCD)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sickle cell disorder</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sub-Saharan Africa</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thalassemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::P Mathematics and Science::PN Chemistry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tribal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vaso-occlusive crisis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>‘Getting to Outcomes’</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Newborn Screening for Sickle Cell Disease and other Haemoglobinopathies is a Special Issue of the International Journal of Neonatal Screening. Sickle cell disease is one of the most common inherited blood disorders, with a huge impact on health care systems due to high morbidity and high mortality associated with the undiagnosed disease. Newborn screening helps to make the diagnosis early and to prevent fatal complications and diagnostic odysseys. This book gives an overview of diagnostic standards in newborn screening for sickle cell disease and examples of existing newborn screening programs.<br/><br/>Listed by <a href="https://unglue.it/work/455786/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/a1/3a/a13a64974f447707f30c8e17c9a5f273.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>20191007</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/427456/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.321704.458655</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>458655</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E101</ProductFormDetail><ProductFormDetail>E116</ProductFormDetail><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>PD-US</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/about/pdm</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Pearls &amp; Parasites</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>A. E. (Arthur Everett) Shipley, Sir</PersonName><PersonNameInverted>Sir, A. E. (Arthur Everett) Shipley,</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Fisheries -- Great Britain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Flies as carriers of disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GITenberg</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Marine animals</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Pasteur, Louis, 1822-1895</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Pearls</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>03</SubjectSchemeIdentifier><SubjectCode>QL</SubjectCode></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>University of Cambridge</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Zebras</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Zoology</SubjectHeadingText></Subject></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div><br/><br/>Listed by <a href="https://unglue.it/work/321704/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/c9/a0/c9a030db54cb40ce0e1a6f9ee945271e.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>Project Gutenberg</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>20160715</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">epub file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/344618/</WebsiteLink></Website><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">mobi file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/344619/</WebsiteLink></Website><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/344620/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.511161.684868</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>684868</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E116</ProductFormDetail><ProductFormDetail>E101</ProductFormDetail><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Regulation of Immunity to Parasitic Infections Endemic to Africa</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Faith H. A. Osier</PersonName><PersonNameInverted>Osier, Faith H. A.</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Jude Ezeh Uzonna</PersonName><PersonNameInverted>Uzonna, Jude Ezeh</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Clinical &amp; internal medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diseases &amp; disorders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fascioliasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Immune response</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immunology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>leishmaniasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>parasitic infections</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>toxoplasmosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>trypanosomiasis</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact<br/><br/>Listed by <a href="https://unglue.it/work/511161/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/21/8f/218fc755867eedda5b562da7ff438847.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>Frontiers Media SA</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2020</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">mobi file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/355127/</WebsiteLink></Website><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">epub file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/354099/</WebsiteLink></Website><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/354098/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.522926.699855</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>699855</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Special Issue in Honor of Professor James D. McChesney on the Occasion of his 80th Birthday</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Muhammad Ilias</PersonName><PersonNameInverted>Ilias, Muhammad</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Dhammika Nanayakkara</PersonName><PersonNameInverted>Nanayakkara, Dhammika</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>1-decanol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>1-octanol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>3-monochloropropane-1,2-diol esters</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>5-epi-machaerifurogerol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anti-inflammatory activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Artocarpus lakoocha</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Atractylodes macrocephala</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>atractylon derivatives</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>autodocking</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>avocado oil</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biology, Life Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biopesticides</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>botanical sources</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Botryosphaeria dothidea</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Calu-3 cell line</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cancer chemotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>charantoside XV</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cucurbitane-type triterpene glycosides</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>deterrent</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DNA damaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>drug resistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>endocyclic and exocyclic diterpene glycosides</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Endophytic fungus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>enzyme kinetics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Ethiopia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fatty acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>flavonoid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GC-FID</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GC-MS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GC/MS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glycerin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glycidyl esters</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glycyrrhizin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gram negative bacteria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HPLC methods</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HPTLC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>in silico study</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>in vitro propagation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>inhibition activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>isoflavonoid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>isoflavonoids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>isolation and identification</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>larvicidal activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>machaeridiol A–C</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>machaerifurogerol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>machaeriol A–C</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Machaerium Rimachi 12161</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Magnoliaceae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mass spectrometry dissociation pattern</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>medicinal crops</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Medicinal plants</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>molecular docking</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Momordica charantia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>monoamine oxidase-B</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mosquito control</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MRSA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>naphtho-γ-pyrones</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neurological disorder</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nigerasperone A</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NMR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oxyresveratrol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Persea americana Mill.</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phytochemistry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phytomedicines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phytotoxin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plant pathogenic fungi</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>poly(ethylene glycol)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>poly(ε-caprolactone)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>polyisoprenylated benzophenones</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pro-oxidant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>process contaminants</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>processing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>propolis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>quality evaluation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>recombinant monoamine oxidase-A</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reference, information &amp; interdisciplinary subjects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Research &amp; information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SARS-CoV-2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>scale up</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Stevia rebaudiana</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>surface plasmon resonance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>teratopyrones</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Teratosphaeria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Torreya taxifolia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>triglyceride</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>UHPLC/ESI-MS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>UHPLC/Q-TOF-MS analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>VRE</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>wheat bran</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>α-amylase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>α-glucosidase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>γ-lactam alkaloids</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Plants have been the sources of important pharmaceuticals, flavoring agents, and agrochemicals. The antimalarial drugs artemisinin and quinine; the anticancer drugs taxol, etoposide, and vinca alkaloids; the sugar-free sweetening agents stevioside and rebaudiosides; and antifeedant azadiractin are good examples of important plant-based drugs, food additives, and agrochemicals currently on the market. Despite these and many other successes, there are significant challenges to discovering and developing commercially important natural products from plants, such as procuring plant materials in large quantities, separating active constituents from complex mixtures, and undesirable qualities, such as low solubility or poor chemical or metabolic stability of active constituents. Dr. James D. McChesney has contributed immensely to overcoming the inherent challenges associated with discovering and developing products modeled from plant-based natural product leads. His research on artemisinin, taxol, galanthamine, podophyllotoxin, and stevia sweet glycosides exemplifies the magnitude of these contributions. His extensive work on the structural modification of taxol led to the discovery and development of the anticancer agent TPI 287, a third-generation taxane analog that is currently undergoing clinical trials. Dr. McChesney has had a long, distinguished teaching and research career, has authored more than 225 research publications, and holds more than 60 patents. He is a past president and Fellow of the American Society of Pharmacognosy and a Fellow of the AAAS. He has mentored many graduate students, post-docs, and junior faculty members who hold prominent positions in natural products research establishments in the US and worldwide. We wish to dedicate this Special Issue Book Version to celebrate the eightieth birthday of Dr. McChesney, a prolific thinker with abundant inventiveness in the field of natural product chemistry and pharmacognosy.<br/><br/>Listed by <a href="https://unglue.it/work/522926/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/51/08/5108f094e5dc2c6ebd588c8d26a28362.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2022</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/369261/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.519917.696095</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>696095</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Synthesis of Marine Natural Products and Molecules Inspired by Marine Substances II</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Emiliano Manzo</PersonName><PersonNameInverted>Manzo, Emiliano</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>(−)-majusculoic acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ADMET</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>animal studies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anti-inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>aureol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Avicennia alba</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biological activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biosynthesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cardiovascular Diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CCK-8</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chemical synthesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Chemistry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cyclomarins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cyclopeptides</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>divergent total synthesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gag polyprotein</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>homology modeling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ilamycins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>In-silico drug design</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>LPS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>marine alkaloids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Marine Natural Products</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>molecular dynamics simulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Natural Products</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reference, information &amp; interdisciplinary subjects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Research &amp; information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rufomycins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tetracyclic meroterpenoids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::P Mathematics and Science::PN Chemistry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>total synthesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Tuberculosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>virtual screening</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This Special Issue, comprising five articles, describes the synthetic methodologies and biological activity of different classes of bioactive marine metabolites and analogs crucial to favor pharmacological applications of these molecules.<br/><br/>Listed by <a href="https://unglue.it/work/519917/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/c4/9f/c49f7ec3038a186965a0664e222b3503.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2021</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/368825/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.404118.550392</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>550392</IDValue></ProductIdentifier><ProductIdentifier><ProductIDType>03</ProductIDType><IDValue>9783038979043</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>The Marrano Phenomenon</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Agata Bielik-Robson</PersonName><PersonNameInverted>Bielik-Robson, Agata</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ambulatory care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Australia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Canada</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Community</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>community pharmacy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>10</SubjectSchemeIdentifier><SubjectCode>EDU000000</SubjectCode><SubjectHeadingText>Education</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>malaria prophylaxis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>multidisciplinary collaboration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pharmacist</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Pharmacists</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Pharmacy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pharmacy law</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Practice</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prescribing and education</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>schedules</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>South Africa</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Switzerland</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Training</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>10</SubjectSchemeIdentifier><SubjectCode>TRV000000</SubjectCode><SubjectHeadingText>Travel</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>travel health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>travel medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>vaccination</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vaccinations</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Vaccines</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This collection of papers describes the recent development of travel health and vaccination services delivered by pharmacists. It is the first dedicated collection of its type and provides a template for the continued growth of pharmacy practice in this area. The articles examine and report on aspects of such services in the UK, US, Canada, Australia, Switzerland, and South Africa, which will provide useful insight for those in other countries developing such pharmacy-based services.<br/><br/>Listed by <a href="https://unglue.it/work/404118/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/35/e6/35e6a456dfa76dbfd50e39f7de6d38c9.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>20190509</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/427491/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.538085.719893</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>719893</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Therapeutic Potential of Plant Secondary Metabolites in the Treatment of Diseases and Drug Development</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Pavel B. Drasar</PersonName><PersonNameInverted>Drasar, Pavel B.</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>alkaloids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>amide bond</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anabolic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anti-HIV activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antimicrobial activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antiviral therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>artemisinin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>betulinic acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bevirimat</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bioavailability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>BODIPY</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cancer cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cannabichromene</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cannabidiol (CBD)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cannabinoid receptors (CB1 and CB2)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cannabinoids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cannabis sativa (Cannabis)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>capsaicinoids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiometabolic diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cell-cycle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Chemical engineering</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chloroquine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COVID-19</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>curcumin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>curcumin analogues</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>curcumin delivery systems</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>curcumin derivatives</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cytotoxicity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Duchenne muscular dystrophy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ecdysteroid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ecdysterone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>EGFR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>endocannabinoidome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fluorescent microscopy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>food intake</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Huisgen 1,3-dipolar cycloaddition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Industrial Chemistry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Industrial chemistry &amp; manufacturing technologies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ivermectin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lignans</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lipid accumulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lipidomics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lipogenesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lung cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>LXRα</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MAFLD</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mas1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>maturation inhibitor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>membrane fusion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Metabolism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microbiota</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MMP2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>molecular ribbon</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>moxidectin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>multifunctional PEG3 derivative</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>natural product</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>natural product synthesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>natural remedy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NF-κB inhibition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NSCLC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Obesity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>onchocerciasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>osteoporosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>overweight</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Papaver somniferum (opium poppy)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PD-L1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phytocannabinoids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phytochemical</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Quinine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>respiratory diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sarcopenia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SARS-CoV-2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>secondary metabolites</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>STAT3</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>supramolecular self-assembly</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tanshinone IIA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Technology, engineering, agriculture</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Technology: general issues</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tetrahydrocannabinol (THC)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thermos-TRPs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>triterpenoid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TRPA1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tumorsphere</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>United States Food and Drug Administration-approved drug</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ursolic acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vinblastine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vincristine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>viral fusion inhibitor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>α,α-dimethylheptyl effect</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>β-ecdysone</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>The importance of natural products, and especially plant secondary metabolites, for the treatment of diseases and drug development has already been obvious in medicine for several thousand years. Thus, this Special Issue of MDPI Biomedicines collects eight top articles from the field as regular full papers in addition to five reviews. All of the published papers are a vibrant source of information on the therapeutic potential of plant secondary metabolites in the treatment of diseases and drug development.<br/><br/>Listed by <a href="https://unglue.it/work/538085/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2022</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/381229/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.302112.431249</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>431249</IDValue></ProductIdentifier><ProductIdentifier><ProductIDType>03</ProductIDType><IDValue>9782889199662</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E101</ProductFormDetail><ProductFormDetail>E116</ProductFormDetail><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Why vaccines to HIV, HCV and Malaria have so far failed - Challenges to developing vaccines against immunoregulating pathogens</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Peter Smooker</PersonName><PersonNameInverted>Smooker, Peter</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Magdalena Plebanski</PersonName><PersonNameInverted>Plebanski, Magdalena</PersonNameInverted></Contributor><Contributor><SequenceNumber>3</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Eric J. Gowans</PersonName><PersonNameInverted>Gowans, Eric J.</PersonNameInverted></Contributor><Contributor><SequenceNumber>4</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Shuo Li</PersonName><PersonNameInverted>Li, Shuo</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Genetics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HCV</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HIV</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immunology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Infectious Disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Influenza</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Vaccine</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Despite continuous progress in the development of anti-viral and anti-bacterial/parasite drugs, the high cost of medicines and the potential for re-infection, especially in high risk groups, suggest that protective vaccines to some of the most dangerous persistent infections are still highly desirable. There are no vaccines available for HIV, HCV and Malaria, and all attempts to make a broadly effective vaccine have failed so far. In this Research Topic we look into why vaccines have failed over the years, and what we have learn from these attempts. Rather than only showing positive results, this issue aims to reflect on failed efforts in vaccine development. Coming to understand our limitations will have theoretical and practical implications for the future development of vaccines to these major global disease burdens.<br/><br/>Listed by <a href="https://unglue.it/work/302112/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>Frontiers Media SA</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2016</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">epub file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/427721/</WebsiteLink></Website><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">mobi file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/315556/</WebsiteLink></Website><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/313904/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product></ONIXMessage>